However, recent reports that documented impaired cognitive development of children with SMA type 1 following SMA-specific genetic treatment (Kölbel et al., 2024) highlight the importance of insights in the longer-term consequences of SMN depletion on development and pathology of the brain. This evidence concerns the gene SMN2 and proximal spinal muscular atrophy.